Skip to content
HowShorted

Nektar Therapeutics short interest in 2018

In 2018, Nektar Therapeutics's disclosed short interest ran from 6.55% of shares outstanding on 12 Jan 2018 to 11.17% on 31 Dec 2018, a change of +4.62 percentage points. The year's high was 11.21% on 30 Nov 2018 and its low 5.91% on 31 Jan 2018, averaging 8.46% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 9.43 days on 31 Aug 2018. Full history: Nektar Therapeutics.

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Nektar Therapeutics in 2018

2018 in figures

Start of year
6.55% (12 Jan 2018)
End of year
11.17% (31 Dec 2018)
Change
+4.62 pp
High
11.21% (30 Nov 2018)
Low
5.91% (31 Jan 2018)
Average
8.46%
Highest days to cover
9.43 (31 Aug 2018)
SEC filings marked
9

Every report in 2018

Nektar Therapeutics short interest in 2018
SettlementShort interestDays to coverFilings since previous
12 Jan 20186.55%3.80results (8-K)
31 Jan 20185.91%3.89
15 Feb 20186.56%2.81
28 Feb 20186.72%5.74
15 Mar 20186.42%3.4010-K filed, results (8-K)
29 Mar 20186.57%1.92
13 Apr 20186.51%4.80
30 Apr 20187.27%4.48
15 May 20186.82%4.8510-Q filed, results (8-K)
31 May 20187.40%4.06
15 Jun 20189.88%1.71
29 Jun 20189.19%2.48
13 Jul 20189.34%7.95
31 Jul 20189.39%8.05
15 Aug 20189.21%7.14results (8-K), 10-Q filed
31 Aug 20189.08%9.43
14 Sep 20189.23%8.35
28 Sep 20189.42%7.28
15 Oct 20188.96%6.87
31 Oct 20189.16%6.01
15 Nov 201810.04%5.18results (8-K), 10-Q filed
30 Nov 201811.21%8.69
14 Dec 201811.03%8.49
31 Dec 201811.17%8.61

See also: Nektar Therapeutics's full history · most shorted US stocks of 2018 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.